Recent Updates
Recently added Catalysts
DWTX Positive Sentiment Score: 75/100

Sent via Electronic Delivery to : angela@virios.com

Wednesday, May 24, 2023 1 min read
Key Takeaway: Virios Therapeutics, Inc. has successfully regained compliance with the Nasdaq Listing Rule 5550(a)(2) after satisfying the minimum bid price requirement. The company's stock closed at $1.00 or above for a consecutive period of 10 business days, which resolves the previously noted compliance issue. This development indicates a positive turnaround for the company's market position.

Market Sentiment Analysis

POSITIVE FACTORS

  • The company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
  • The closing bid price has been at $1.00 or greater for the last 10 consecutive business days.
  • The matter regarding compliance is now closed.

Full Press Release Details

Sent via Electronic Delivery to: angela@virios.com
Senior Vice President of Finance and Corporate Secretary Virios Therapeutics, Inc.
Alpharetta, GA 30009
On November 1, 2022, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Staff has determined that for the last 10 consecutive business days, from May 10, 2023 to May 23, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
If you have any questions, please contact Patryk Muter, at +1 301 532 6389.
Nasdaq Listing Qualifications

Frequently Asked Questions

What notification did Virios Therapeutics receive on November 1, 2022?

On November 1, 2022, Virios Therapeutics was notified that its stock fell below a $1.00 bid price.

What is the Nasdaq Listing Rule 5550(a)(2)?

Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 for compliance.

When did Virios regain compliance with Nasdaq rules?

Virios regained compliance from May 10 to May 23, 2023, maintaining a $1.00 bid price.

Who can be contacted for more information on this matter?

Patryk Muter can be contacted at +1 301 532 6389 for more details.

Tags: DWTX Viatris Investor Conferences Healthcare Virios Therapeutics Nasdaq stock compliance bid price
Last updated: May 24, 2023